SVA — Sinovac Biotech Income Statement

0.000.00%

Last trade - 00:00

HealthcareMicro Cap

Annual income statement for Sinovac Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	R2021 December 31st	R2022 December 31st	R2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	20-F	20-F	20-F	20-F	20-F
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	19,365	1,473	470	361	386
Cost of Revenue
Gross Profit	18,376	815	323	221	262
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,747	1,982	1,184	867	876
Operating Profit	17,618	-509	-714	-506	-490
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	17,568	-48.5	-84.5	42.8	-262
Provision for Income Taxes
Net Income After Taxes	14,120	-60	-121	40.7	-199
Minority Interest
Net Income Before Extraordinary Items
Net Income	8,122	14.5	-13.5	90.9	-59.7
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	8,122	14.5	-13.5	90.9	-59.7
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	113	0.255	0.796	1.66	1
Special Dividends per Share